Boehringer Ingelheim Corporation to Announce Pivotal Phase III Hepatitis C Data for Faldaprevir* at American Association for Study of Liver Diseases Congress 2013

Published: Oct 01, 2013

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

For media outside of the U.S.A., UK and Canada only

Ten abstracts featuring Boehringer Ingelheim’s investigational hepatitis C virus (HCV) protease inhibitor, faldaprevir*and polymerase inhibitor, deleobuvir* will be presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) 2013, 1-5 November, Washington.1

Help employers find you! Check out all the jobs and post your resume.

Back to news